on behalf of the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation Few studies have evaluated the risk factors for chronic GVHD and organ involvement associated with different graft types, including unrelated cord blood (U-CB). We retrospectively studied 4818 adult patients who received their first allogeneic transplantation and survived for at least 100 days. The incidence of chronic GVHD at 2 years was 37%. The following factors were associated with the development of chronic GVHD: female donor/male recipient, CMV-Ab seropositivity, matched related peripheral blood grafts vs matched related BM grafts, no in vivo T-cell depletion and the occurrence of grade II-IV acute GVHD. Among these factors, the association with acute GVHD occurrence was consistently significant across donor subtypes. The use of U-CB was not associated with chronic GVHD, but was associated with a low incidence of extensive chronic GVHD. Chronic GVHD patients who had received U-CB transplants showed less frequent involvement of the oral cavity (28% vs 55%), eye (12% vs 26%), liver (20% vs 44%), lung (11% vs 25%) and joint (0% vs 6%) than those with matched related BM grafts. In conclusion, we found that U-CB transplants were associated with a low incidence of extensive chronic GVHD and less frequent involvement of the oral cavity, eye, liver, lung and joints.
INTRODUCTION
Chronic GVHD is a serious complication that affects the survival and quality of life of long-term survivors after allogeneic hematopoietic SCT. [1] [2] [3] Various pre-and post-transplant risk factors associated with chronic GVHD have been identified, mostly in transplantations using BM and PBSC grafts from related or unrelated donors. 2, 3 Several studies have reported a history of acute GVHD to be a strong risk factor that is consistently associated with chronic GVHD development. [4] [5] [6] [7] [8] Other identified risk factors include the following: female donor and male recipient, 4, 6 use of PBSC grafts, 6, [9] [10] [11] [12] [13] older patient, 4, [6] [7] [8] older donor, 6 ,7 transplantation from a mismatched or unrelated donor, 5, 6, 14 diagnosis of CML 4, 7, 8 and absence of anti-thymocyte globulin (ATG) use. 15 The number of unrelated cord blood (U-CB) transplantations performed has rapidly increased during the past decade. However, few studies have compared the incidences and risk factors of chronic GVHD and its organ-specific symptoms in adult patients receiving U-CB and other available grafts, including related or unrelated BM/PBSC grafts. 16, 17 Therefore, we conducted a retrospective study using national registry data involving 4818 patients who underwent allogeneic transplantation. This study aimed to evaluate the incidence and risk factors of chronic GVHD, and the prevalence of chronic GVHD organ involvement in patients who received transplantation using various types of graft, including U-CB.
MATERIALS AND METHODS

Data collection
Data for 54 072 patients who had received auto-SCT or allo-SCT by December 31, 2009 were provided by the Transplant Registry Unified Management Program (TRUMP). 18 We included 4993 adult patients who had: (1) received allogeneic transplantation for hematologic malignancies; (2) received their first SCT; (3) used the same questionnaire form involving chronic GVHD organ involvement (skin, oral cavity, eye, liver, lung, joint, intestine/genitals and other manifestations; 2006-2009 for transplantations using BM or PBSC grafts and 2007-2009 for transplantations using U-CB units); (4) achieved neutrophil engraftment; (5) survived for at least 100 days; and (6) received the following: (a) a related BM or PBSC graft (R-BM/PB), (b) an unrelated BM (U-BM) or (c) a single U-CB unit. Donation of peripheral blood by unrelated volunteers was permitted for the first time in Japan in 2011. The following patients were excluded: (1) patients who received ex vivo T-cell-depleted grafts (n ¼ 26) and (2) patients who lacked data on acute or chronic GVHD (n ¼ 149). Thus, 4818 patients were included in this study, which was approved by the TRUMP Data Management Committees and by the institutional review board of the Nagoya University Graduate School of Medicine, where this study was performed.
matching was assessed using serological data for the HLA-A, HLA-B and HLA-DR loci in R-BM/PB or U-CB transplantations, and using allelic data for the HLA-A, HLA-B and HLA-DRB1 loci in U-BM transplantations.
Statistical analysis
The physicians who performed the transplantations at each center diagnosed and classified acute and chronic GVHD according to traditional criteria. 1, 19 The reported type of chronic GVHD was reclassified according to the information on its organ involvement. 'Progressive onset' of chronic GVHD was defined as chronic GVHD transitioned from active acute GVHD, 'quiescent onset' as chronic GVHD after remission of acute GVHD and 'de novo onset' as chronic GVHD without history or acute GVHD. The intensity of conditioning regimen was classified as myeloablative or reduced intensity on the basis of the Center for International Blood and Marrow Transplant Research report and the information from the questionnaire, as previously described. [20] [21] [22] [23] We defined the following as standard-risk diseases: AML and ALL in first or second remission; CML in the first or Male to female  398  21  573  26  109  15  Female to male  496  27  389  18  131  18  Missing  0  0  2  0  277  37   Disease  AML  799  43  986  45  395  53  0.004  MDS  210  11  276  12  76  10  CML  60  3  73  3  25  3  ALL  385  21  439  20  123  17  ATL  110  6  131  6  29  4  NHL  206  11  214  10  70  9  Other diseases  89  5  96  4 Data are missing in 20 patients b HLA matching was assessed by serological data for HLA-A, HLA-B and HLA-DR loci in transplantation using R-BM/PB or U-CB grafts, whereas it was assessed by allelic data for HLA-A, HLA-B and HLA-DRB1 loci in transplantation using U-BM grafts.
Chronic GVHD in Japan J Kanda et al second chronic phase or in the accelerated phase; myelodysplastic syndrome (MDS) with refractory anemia or refractory anemia with ringed sideroblasts; adult T-cell leukemia (ATL) in CR; and Hodgkin's or nonHodgkin's lymphoma (NHL) in CR or PR. Others were defined as high-risk diseases.
The probability of developing chronic GVHD was estimated on the basis of cumulative incidence curves. 24 Competing events for chronic GVHD were death or relapse without GVHD. Groups were compared using Gray's test. 25 The Cox proportional hazards model was used to evaluate the effect of confounding variables on chronic GVHD. The following possible confounding variables were considered: recipient age; recipient sex; sex mismatch between recipient and donor (match, male (donor)/female (recipient), or female (donor)/male (recipient)); disease (CML or others); disease risk before transplantation (standard or high risk); donor type (HLA-matched related BM (MR-BM), HLA-matched related PBSCs (MR-PB), HLA-mismatched related BM (MMR-BM), HLA-mismatched related PBSCs (MMR-PB), HLA-matched unrelated BM (MU-BM), HLA-mismatched unrelated BM (MMU-BM) and U-CB); type of conditioning regimen (myeloablative or reduced intensity); type of GVHD prophylaxis (CsA based or tacrolimus based); use of in vivo T-cell depletion (yes or no); anti-CMV Ab detection (negative for both recipient and donor, or positive for either recipient or donor), and presence of grade II-IV acute GVHD. Confounding factors were selected in a stepwise manner from the model with a variable retention criterion of Po0.05. Reported factors associated with chronic GVHD (recipient age, sex mismatch, donor type, use of in vivo T-cell depletion and the presence of grade II-IV acute GVHD) was additionally selected as confounding factors in the analysis of chronic GVHD risk. In the subset analysis, the same variables used in the analysis for the entire cohort were added to the final model. Furthermore, the following variables were also added for the specific group: donor age, presence of an HLA mismatch and the use of PBSCs for the R-BM/PB group; donor age and presence of an HLA mismatch for the U-BM group; and presence of an HLA mismatch for the U-CB group.
We also compared the prevalence of chronic GVHD presentation or organ involvement between MR-BM and other graft types using the w 2 test. We further evaluated chronic GVHD-specific survival, which is defined as the time from the day of chronic GVHD diagnosis to the day of death in the absence of relapse, among patients who developed chronic GVHD. We also evaluated OS among those who developed chronic GVHD. The probability of developing chronic GVHD-specific survival or OS from the onset of chronic GVHD was estimated using the Kaplan-Meier method, and univariate comparison between groups was performed using the log-rank test. In the analysis of chronic GVHD-specific survival, patients who were alive without disease recurrence were censored at the time of their last follow-up visit and those who experienced disease recurrence were censored at the time of diagnosis of recurrence. The Cox proportional hazards model was used to evaluate the effect of presentation or of each organ's manifestation of chronic GVHD on chronic GVHD-specific survival, after adjusting for donor type and other confounding factors that were selected from the model in a stepwise manner using a variable retention criterion of Po0.05. We also evaluated the effect of chronic GVHD on relapse, where the occurrence of chronic GVHD was treated as a timevarying covariate.
All tests were two-sided, and P-values o0.05 were considered statistically significant, except for the comparison of prevalence of chronic GVHD organ involvement between MR-BM and other graft types, where Pvalues o0.008 was significant in consideration of multiple comparison. All statistical analyses were performed using Stata version 12 (Stata Corp., College Station, TX, USA) and EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), 26, 27 which is a graphical user interface for R (R Foundation for Statistical Computing, version 2.13.0, Vienna, Austria). Table 1 shows patient characteristics according to the stem cell source. The median age of recipients at the time of the transplant was 47 years (range, 16-82 years) for the entire cohort, and it was significantly higher for patients in the U-CB group. High-risk diseases were more prevalent in the U-CB group. The grafts used were MR-BM (n ¼ 687), MR-PB (n ¼ 799), MMR-BM (n ¼ 155), MMR-PB (n ¼ 218), MU-BM (n ¼ 1507), MMU-BM (n ¼ 708) and U-CB (n ¼ 744). CsA-based GVHD prophylaxis was received by 74% of the patients in the R-BM/PB group and by only 21% of the U-BM recipients. In vivo T-cell depletion was used for only 4% of the entire cohort (ATG, n ¼ 197; alemtuzumab, n ¼ 7). Grade II-IV and III-IV acute GVHD occurred in 39% and 11% of the cohort, respectively.
RESULTS
Patient characteristics
Chronic GVHD The incidence of chronic GVHD at 2 years was 37% (95% confidence interval (CI), 35-38%) for the entire cohort, with a median onset of 120 days (range, 30-1203 days), 36% (32-39%) for the MR-BM group, 48% (44-51%) for the MR-PB group, 40% (32-48%) for the MMR-BM group, 37% (30-44%) for the MMR-PB group, 34% (31-36%) for the MU-BM group, 40% (36-44%) for the MMU-BM group and 30% (27-34%) for the U-CB group (Gray's test for the whole group, Po0.001; Figure 1a ). Female/male mismatch between recipient and donor (hazard ratio (HR), 1.29; Po0.001), CMV Ab detection (HR, 1.26; P ¼ 0.015), the use of MR-PB vs MR-BM graft (HR, 1.49; Po0.001), the use of in vivo T-cell depletion (HR, 0.48; Po0.001) and the occurrence of grade II-IV acute GVHD (HR, 1.62; Po0.001) were significantly associated with chronic GVHD development ( Table 2 ). The use of PBSC grafts was significantly associated with chronic GVHD development in the R-BM/PB group (HR, 1.42; Po0.001). The impact of CMV Ab positivity on chronic GVHD development was significant only for the U-CB group, but HR was consistently high across donor subtypes. The effect of sex mismatch was significant for the R-BM/ PB group, but was not significant for the U-CB group. The effect of grade II-IV acute GVHD occurrence on chronic GVHD development was consistently significant across donor subtypes. Chronic GVHD in Japan J Kanda et al
Extensive chronic GVHD The incidence of extensive chronic GVHD at 2 years was 30% (29-31%) for the entire cohort, 32% (28-35%) for the MR-BM group, 42% (39-46%) for the MR-PB group, 31% (24-39%) for the MMR-BM group, 33% (26-39%) for the MMR-PB group, 27% (25-29%) for the MU-BM group, 32% (28-36%) for the MMU-BM group and 19% (17-22%) for the U-CB group (Gray's test for the whole group, Po0.001; Figure 1b) . In addition to being a significant variable in the analysis of chronic GVHD, the use of reduced-intensity conditioning (vs myeloablative conditioning) was inversely associated with the development of extensive chronic GVHD (HR, 0.86; P ¼ 0.019; Table 3 ). Compared with MR-BM, MR-PB and MMR-PB were associated with the development of extensive chronic GVHD, whereas MU-BM and U-CB grafts were inversely associated with its development. Grade II-IV acute GVHD occurrence was the only significant variable consistently observed across all donor types.
Organ-specific chronic GVHD Figure 2 shows the type of presentation and organ involvement associated with chronic GVHD. Among the 1716 patients who developed chronic GVHD, de novo, progressive and quiescent chronic GVHD presentations were observed in 467 (27%), 348 (20%) and 901 (53%) patients, respectively. Compared with the MR-BM group, progressive chronic GVHD was more frequently observed in the MMU-BM group (33% vs 15%), and quiescent chronic GVHD was more frequently observed in the U-CB group (62% vs 53%). Limited type of skin involvement was more frequently observed in the U-CB group than in the MR-BM group (53% vs 29%). We examined the types of chronic GVHD (limited vs extensive) in patients with limited type of skin GVHD to evaluate the effect of limited type of skin GVHD on chronic GVHD type in the U-CB group. Accordingly, extensive chronic GVHD was observed in 73% of patients with limited type of skin GVHD in the MR-BM group, compared with 49% of patients in the U-CB group. Oral cavity (28% vs 55%), eye (12% vs 26%), liver (20% vs 44%), lung (11% vs 25%) and joint (0% vs 6%) involvement was less prevalent in the U-CB group than in the MR-BM group. There was no organ that was more frequently involved in the U-CB group than in the MR-BM group.
Progressive onset of chronic GVHD, extensive skin GVHD, intestinal or genital involvement and extensive type of chronic GVHD were significantly associated with lower chronic GVHDspecific survival rates in multivariate analysis, after adjusting for other confounders (Table 4) . Lung involvement in GVHD was marginally significant. On the other hand, limited type of skin GVHD was associated with higher chronic GVHD-specific survival rates. Chronic GVHD-specific survival and OS curves showing a significant difference between the groups are shown in Figure 3 and Supplementary Figure 1 . The impact of chronic GVHD on relapse is also an important issue. The occurrence of chronic GVHD was significantly associated with lower incidence of relapse than the absence of chronic GVHD for the total cohort (HR 0.88, P ¼ 0.018). However, we did not find any significant different impact of type, onset and organ involvement of chronic GVHD on relapse among those with chronic GVHD.
DISCUSSION
In the present study, we extensively analyzed the risk factors for chronic GVHD, particularly focusing on donor graft sources and organ involvement, using recently obtained national registry data that included a large number of U-CB transplantations. In addition to confirming previously reported chronic GVHD risk factors, we observed a lower incidence of extensive chronic GVHD in recipients of U-CB than in recipients of MR-BM. Moreover, in patients with chronic GVHD, oral cavity, eye, liver, lung and joint involvement was substantially lower in the U-CB group than in the MR-BM group. Grade II-IV acute GVHD occurrence was a strong risk factor for chronic and extensive chronic GVHD, regardless of the donor type, which is consistent with previous findings. [4] [5] [6] [7] The mechanism through which chronic GVHD develops is considered to be different from that of acute GVHD, 28 and the underlying mechanism by which acute GVHD strongly influences chronic GVHD development remains unknown. Acute GVHD causes thymic epithelial damage and functional deterioration, leading to a decrease in thymic output, represented by low T-cell receptor excision circle levels. 29 The association between low T-cell receptor excision circle levels and occurrence of chronic GVHD was reported in HLA-identical sibling transplantation, 30 which may partly explain the association between the history of acute GVHD and the development of chronic GVHD. The combination of female donor/male recipient was significantly associated with the development of chronic GVHD, which is also consistent with previous studies. 4, 6 In the subset analysis, the combination of female donor/male recipient was significant for the R-BM/PB group, but not significant for the U-CB group. T cells transplanted from adult female donors can be activated by exposure to Y-chromosome-associated proteins and may cause chronic GVHD, but those from female U-CB units may be less activated against them. 31 Studies on the effect of the CMV Ab on chronic GVHD development have previously yielded controversial results. 2, 32 In this study, we observed a significant impact of CMV seropositivity on the incidences of chronic GVHD and extensive chronic GVHD. However, the presence of antigenemia itself was not a significant factor in univariate analysis (data not shown); therefore, the mechanism through which CMV Ab affects chronic GVHD development remains unknown. We also confirmed that the use of a PBSC graft vs a BM graft constituted a strong risk factor for chronic and extensive chronic GVHD development in the R-BM/PB group. On the other hand, the use of ATG was associated with a lower incidence of chronic GVHD, particularly in the R-BM/PB group. Contrary to previous reports, HLA disparity did not have a strong effect on chronic GVHD development in the R-BM/PB group. In addition, the use of MU-BM grafts was significantly associated with a lower incidence of extensive chronic GVHD. These findings may indicate that GVHD prophylaxis was intensified according to the acknowledged risk of GVHD. Therefore, we performed the same analysis after excluding the use of ATG or in the subgroup of patients who used tacrolimus or CsA as GVHD prophylaxis. However, we obtained the same result, which suggests that some other factor, such as the timing of immunosuppressive agent tapering, may be affecting the results. In the analysis of chronic GVHD-specific survival, extensive type (vs limited type), progressive onset (vs de novo onset), extensive skin involvement (vs none), no skin involvement (vs limited involvement), and intestinal or genital involvement were associated with lower chronic GVHD-specific survival rate. The impact of quiescent onset chronic GVHD has been controversial, 2, 33 but chronic GVHD-specific survival in the patients showing quiescent onset chronic GVHD was almost comparable to those showing de novo onset in line with several recent reports. 5, 34 Although oral involvement was not associated with lower chronic GVHD-specific survival, which is compatible with a previous report, 35 intestinal or genital involvement was associated with lower survival rate. The use of U-CB was not associated with chronic GVHD-specific survival, even when only patients with extensive chronic GVHD were considered (data not shown). This finding suggests that chronic GVHD, if it occurs, does not behave differently regardless of the stem cell source. On the other hand, oral cavity, eye, liver, lung and joint involvement were substantially lower in the U-CB group, which contributed to the significantly lower incidence of extensive GVHD in the U-CB than in the MR-BM group. The high incidence of early TRM, such as that involving graft failure and infection, is considered a disadvantage of U-CB transplantations. However, if a patient survives the first few months following U-CB transplantation without treatment-related complications, the risk of extensive GVHD and GVHD-associated treatment-related complications would then be lower than in other transplantations. The low incidence of chronic GVHD would also contribute to the early discontinuation of immunosuppressive agents, which would allow or even promote immune reconstitution in long-term survivors of U-CB transplantation. Therefore, the choice of using U-CB as an alternative graft source might be prioritized if early treatment-related complications can be avoided through new approaches to ensure engraftment and enhance early immune reconstitution. Several limitations of this study should be noted. First, in this study, acute and chronic GVHD were diagnosed on the basis of traditional criteria, whereas chronic GVHD was diagnosed and classified on the basis of NIH criteria in recent studies. [36] [37] [38] [39] Therefore, our results cannot be compared with those reported in other studies. In addition, it is possible that late onset acute GVHD was classified as chronic GVHD or early onset of chronic GVHD was defined as acute GVHD. This may bias the association between acute and chronic GVHD. Second, there is a possibility that chronic GVHD that developed a few years after SCT was not reported or was missed. Furthermore, detailed information on the clinical course of GVHD and on the onset of each chronic GVHD organ manifestation was not available; therefore, chronic GVHD-specific survival should be cautiously interpreted. Fourth, because organ involvement of chronic GVHD was not defined in detail in this large retrospective studies, there is a possibility of misclassification regarding organ involvement. Further, the information on intestinal or genital involvement was not separately collected in the questionnaire. Lastly, incidence of chronic GVHD in the present study was relatively low as compared with that in Caucasian cohorts, suggesting that the genetic differences between races may affect occurrence of chronic GVHD. Therefore, the results should be cautiously interpreted when the result is applied for non-Asian populations.
In conclusion, extensive chronic GVHD was less frequently observed in the U-CB group. In addition, among patients who developed chronic GVHD, oral cavity, eye, liver, lung and joint involvement were less frequently observed in the U-CB group. Although limited type of skin GVHD was frequently observed, it remains within the range of limited chronic GVHD. Therefore, the quality of life may be better for long-term survivors of the U-CB group than those of the MR-BM group or the other groups. Progressive onset, extensive chronic GVHD or intestinal or genital involvement was associated with lower chronic GVHD-specific survival, which suggests the need to intensify treatment for patients with these chronic GVHD characteristics. Finally, a prospective study using NIH criteria is needed to compare the Chronic GVHD in Japan J Kanda et al incidences of patients with chronic GVHD between Japan and other countries.
